Anavex Life Sciences (AVXL) Interest Coverage Ratio Growth (1y) (2017 - 2025)
Anavex Life Sciences (AVXL) Interest Coverage Ratio Growth (1y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -347.04% |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn | 1,378.45% |
| 10 | Anavex Life Sciences | 223.02 Mn | 91.27 Mn | - | 98.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 98.87% |
| Sep 30, 2025 | 99.82% |
| Jun 30, 2025 | 83.85% |
| Mar 31, 2025 | 67.98% |
| Dec 31, 2024 | 17.59% |
| Sep 30, 2024 | 72.76% |
| Jun 30, 2024 | -464.32% |
| Mar 31, 2024 | -211.56% |
| Dec 31, 2023 | 21.38% |
| Sep 30, 2023 | -131.37% |
| Jun 30, 2023 | -63.50% |
| Mar 31, 2023 | -128.43% |
| Dec 31, 2022 | -241.81% |
| Sep 30, 2022 | -126.73% |
| Jun 30, 2022 | -122.29% |
| Mar 31, 2022 | -115.22% |
| Dec 31, 2021 | -113.89% |
| Sep 30, 2021 | 52.43% |
| Jun 30, 2021 | 49.38% |
| Mar 31, 2021 | 255.06% |